Pediatric Hematology & Oncology
A section of Children (ISSN 2227-9067).
Section Information
The Pediatric Hematology & Oncology Section accepts articles related to the diagnosis and treatment of benign hematologic conditions, childhood and adolescent cancers, and hematopoietic stem cell transplantation for benign and malignant conditions. Articles can focus on therapy, supportive care, long-term outcomes/survivorship, epidemiology and disease prevention, and the economic impact of these diseases (both on the patient and the health care system). Clinical trials and observational studies (cohort studies, case-control studies) are preferred, but systematic reviews/meta-analyses are also welcome as long as they are methodologically rigorous. Case reports will only be considered if they report on a novel finding with important clinical implications.
- Childhood cancer
- Benign hematology
- Hematopoietic stem cell transplant
- Adolescents
- Survivorship/late effects
- Health economics
- Health services research
- Clinical trials
- Solid tumors
- Brain tumors
- Leukemia and lymphoma
- Thrombosis and hemostasis
- Hemoglobinopathies
- Bone marrow failure syndromes
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Revolutionizing Pediatric Blood Cancer Treatment: Advances in Targeted Immunotherapy for Leukemia and Lymphomas (Deadline: 30 September 2025)
- Childhood Hematologic and Oncologic Diseases: Emerging Insights and Next-Generation Solutions (Deadline: 15 January 2026)
- Psychological Support in Pediatric Oncology: Improving Clinical Outcomes and Quality of Life (Deadline: 30 January 2026)
- Genetics and Precision Medicine with Hematologic Diseases in Children (Deadline: 1 February 2026)
